Connect with us

Medical Discovery

A new discovery of DNA will change many concepts

Published

on



A new discovery of DNA will change many concepts
Mysterious new form of DNA seen inside human cells for the first time looks like a ‘twisted knot’ instead of a double helix

Knotty new DNA structure found in living cells for the first time

In human cells, scientists find DNA that looks like a twisted knot instead of a double helix

Researchers Discover New DNA Structure Within Human Cells

Biologists have recently discovered a new DNA structure in living cells.

The new find has been called the “twisted knot” of DNA, and it shows just how complex human DNA is beyond the modern understanding of a double-helix structure.
DNA Genesis – The Children Of Adam – National Geographic Documentary Films – Full HD Documentaries
15 Interesting DNA Facts
Scientists Shocking Discovery That Melanesians Carry DNA of Unknown Human Species
Message found in human DNA at Harvard university
How to sequence the human genome – Mark J. Kiel
Scientists Discovered Message from God in Human DNA Code!!
6 SIGNS You May Have ALIEN DNA
Part 1: Human DNA Mysteries – The Mechanics of Ascension
The study was led by professor Daniel Christ who serves as head of the Antibody Therapeutics lab at the Garvan Institute of Medical Research. According to Christ, this find upends what neary everyone has come to understand about DNA over the last several decades.

The new DNA bit is called the intercalated motif (i-motif) structure. While this particular find was discovered in the 1990s, it’s only just now finally been seen in living cells. (Prior to the most recent discovery, eveything else had been observed through in vitro methods.)

“The i-motif is a four-stranded ‘knot’ of DNA,” explained Associate Professor Marcel Dinger (Head, Kinghorn Centre for Clinical Genomics, Garvan), who co-led the research with associate professor Christ.

**************************************
Thank you for watching the video and do not forget to subscribe to the channel for you all new
**************************************
Subscribe:
Facebook:
Follow us on Twitter:
**************************************
This channel is interested in:
#art
#Sports
#Cultures
#News
#Politics
#History
#games
#Humanity
#kids
#MMA
#UFC

-~-~~-~~~-~~-~-
Please watch: “Selena Gomez Has MOVED ON From Justin Bieber & Not At All Interested In Getting Back Together ”

-~-~~-~~~-~~-~-

Continue Reading
2 Comments

2 Comments

  1. GO TUBE

    April 24, 2018 at 1:55 pm

    The new DNA bit is called the intercalated motif (i-motif) structure. While this particular find was discovered in the 1990s, it's only just now finally been seen in living cells. (Prior to the most recent discovery, eveything else had been observed through in vitro methods.)

  2. L.C. Kimsey

    April 30, 2018 at 7:43 am

    The G quadraplex and Imotif are substantial discoveries and it will revolutionize many things in the medical community and how cancer, diabetic, and autoimmune diseases are treated through gene expression and no longer needing to change the pH balance in order to switch the nanotech on and off or ravel and unravel

Leave a Reply

Your email address will not be published. Required fields are marked *

Medical Discovery

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Published

on

By



Learn about a recent collaboration with Novartis Pharmaceuticals, which utilizes a deep neural network to accelerate image analysis in early drug discovery by detecting and targeting exactly which cells in the body need treatment.

Read the article:

Keep up to date with the IDZ Weekly Youtube Playlist:

Subscribe to the Intel Software YouTube Channel:

About Intel Software:
The Intel® Developer Zone encourages and supports software developers that are developing applications for Intel hardware and software products. The Intel Software YouTube channel is a place to learn tips and tricks, get the latest news, watch product demos from both Intel, and our many partners across multiple fields. You’ll find videos covering the topics listed below, and to learn more, you can follow the links provided!

Connect with Intel Software:
Visit INTEL SOFTWARE WEBSITE:
Like INTEL SOFTWARE on FACEBOOK:
Follow INTEL SOFTWARE on TWITTER:

INTEL SOFTWARE GITHUB:
INTEL DEVELOPER ZONE LINKEDIN:
INTEL DEVELOPER ZONE INSTAGRAM:
INTEL GAME DEV TWITCH:

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Joao Monteiro, MD, PhD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Janet Woodcock, MD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Trending